Adjunctive Resveratrol or Omeprazole in Patients with Non-Transfusion-Dependent Thalassemia with Iron Overload: A Randomized, Double-Blind, Placebo-Controlled Trial
In brief
Resveratrol and omeprazole show no significant iron-overload benefit in 30 adults
In this six-month trial of adults with non-transfusion-dependent thalassemia on stable chelation, ferritin fell numerically with resveratrol or omeprazole, but neither treatment significantly outperformed placebo on ferritin or other iron-related measures. Both were generally well tolerated, with no serious adverse events; the small, underpowered trial leaves open whether larger studies would find a benefit.
- Journal
- International journal of molecular sciences (Q1)
- Published
- 6 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Thanapong Chopetgool, Chatree Chai-Adisaksopha, Ekarat Rattarittamrong, Lalita Norasetthada, Thanawat Rattanathammethee, Sasinee Hantrakool, et al.
- PMID
- 43028182
- DOI
- 10.3390/ijms27219939
Why clinicians should know about it
- Picked for Biochemistry (medical) (paper of the day, 17 November 2026): Randomized iron-overload trial measures ferritin and iron-regulatory biochemistry
- Picked for Hematology (top studies of the week, 15 November 2026): Randomized trial of adjunctive iron-overload treatment in NTDT
Abstract
Increased gastrointestinal iron absorption contributes substantially to iron overload in non-transfusion-dependent thalassemia (NTDT) patients. Resveratrol (RVT) and omeprazole (OMP) may reduce intestinal iron absorption and potentially complement iron chelation therapy. This randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of adjunctive RVT or OMP in adults with NTDT receiving stable iron chelation therapy. The primary outcome was the change in serum ferritin; secondary outcomes influenced serum iron (SI), transferrin saturation (TS), erythroferrone (ERFE), hepcidin, fetal hemoglobin (HbF), and safety. Participants with serum ferritin ≥ 300 ng/mL were randomized (1:1:1) to receive RVT 250 mg, OMP 20 mg, or the placebo (PLA) twice daily for 6 months. Thirty participants were randomized (RVT, n = 10; OMP, n = 11; PLA, n = 9), with a baseline median serum ferritin value of 629 ng/mL, interquartile range (IQR) 484-975. Serum ferritin decreased numerically over 6 months in the RVT and OMP groups relative to PLA; however, no significant treatment × time interactions or adjusted between-group differences in changes from the baseline were observed. Although significant within-group changes were observed for selected iron-regulatory biomarkers, including hepcidin, ERFE, and TS, these were not accompanied by significant treatment × time interactions and did not demonstrate differential treatment effects. Both interventions were generally well tolerated, and no serious adverse events were reported. In this underpowered trial, neither adjunctive RVT nor OMP demonstrated statistically significant treatment-specific effects on serum ferritin or other iron-related outcomes when compared with the placebo. The observed numerical trends warrant evaluation in larger, adequately powered trials. Trial Registration: ISRCTN73258526.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.